This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Achillion CEO Needs to Deliver on Deal Talk

Stock quotes in this article: ACHN, ANDS, INHX, IDIX, GILD, VRTX

BOSTON ( TheStreet) -- It's a well-worn page in the investor conference presentation script: Biotech CEO takes stage and tells assembled audience of investors that his drugs have the makings to be best in class and that potential Big Pharma partners are all very interested in a deal.

This is pretty much what investors heard from Achillion Pharmaceuticals (ACHN) CEO Michael Kishbauch Wednesday during his twirl through the Stifel Nicolaus Healthcare Conference.

Achillion expects to release proof-of-concept data from studies of three different experimental hepatitis C drugs before the end of the year, said Kishbauch. Among the expected results are 12-week, early virologic response data from a mid-stage study of Achillion's experimental protease inhibitor ACH-1625 combined with interferon and ribavirin.

Interest from Big Pharma in licensing or acquiring Achillion's Hep C drugs has increased since a spring Hep C research meeting in Europe, Kishbauch claims.

"Our talks have become intense," he said.

Talk is cheap, of course. Kishbauch leaves out the part in which Achillion is just one of many smaller Hep C drug developers desperate to find a big-moneyed partner. Anadys Pharmaceuticals (ANDS), Idenix Pharmaceuticals (IDIX) and Inhibitex (INHX), to name a few, are all saying singing the same tune.

This is not to say that deals won't get done or that Kishbauch is lying, it's just that for all the endless chatter and optimism about buyouts or lucrative partnerships amongst Hep C drug developers, actual deal activity has been rather anemic.

It's much easier to talk about deals than getting them done, apparently.

And it's not like Achillion hasn't gone down this road before. Achillion licensed a promising Hep C drug to Gilead Sciences (GILD) but that drug blew up in 2007 due to safety problems and was discontinued.

The Hep C treatment market is changing fast. The launch this spring of Vertex Pharmaceuticals' (VRTX) Incivek and Merck's (MRK) Victrelis dramatically improved the outlook for patients, but better drugs, better combinations of drugs, are on the way. Achillion is late to the game but hopes to play catch up by developing drugs that can be combined together to create more effective, all oral treatment options. (That means getting rid of weekly shots of interferon.)

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,873.26 -169.64 -1.00%
S&P 500 1,959.37 -12.92 -0.66%
NASDAQ 4,452.5950 -40.7950 -0.91%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs